Brepocitinib

Brand names: Lisraya · Active ingredient: Brepocitinib Tosylate

In short: LISRAYA is indicated for the treatment of dermatomyositis in adult patients. Limitations of Use LISRAYA is not recommended for use in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.

Forms & strengthsTablets: 30 mg of brepocitinib; pink, capsule-shaped, immediate-release, film-coated, and debossed with “BT30” on one side
LabelPriovant Therapeutics, Inc.
Label updatedNov 05, 2026

What is Brepocitinib used for?

LISRAYA is indicated for the treatment of dermatomyositis in adult patients.

Limitations of Use

LISRAYA is not recommended for use in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.

⚠ Boxed warning (FDA's strongest warning)

SERIOUS INFECTIONS

Patients treated with LISRAYA are at increased risk of developing serious bacterial, fungal, viral, and opportunistic infections that may lead to hospitalization or death.

Reported infections with use of Janus kinase (JAK) inhibitors, including LISRAYA:

Active tuberculosis (TB), which may present with pulmonary or extrapulmonary disease. Evaluate and test patients for latent and active TB infection prior to and during LISRAYA treatment. If positive, treat for TB. Monitor all patients for active TB during treatment including patients who tested negative of a latent TB infection prior to LISRAYA treatment.

Invasive fungal infections. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.

Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.

Avoid use of LISRAYA in patients with an active, serious infection, including localized infections. Consider the risks and benefits of LISRAYA in patients with chronic or recurrent infection prior to initiating treatment. Closely monitor patients for signs and symptoms of infection during and after treatment with LISRAYA. If a serious infection occurs, interrupt LISRAYA treatment until the infection resolves or is adequately treated

.

MORTALITY

A higher rate of all-cause mortality, including sudden cardiovascular death was observed with another Janus kinase (JAK) inhibitor when compared to tumor necrosis factor (TNF) blockers in patients with rheumatoid arthritis (RA)

.

LISRAYA is not approved for use in patients with RA. …

Brepocitinib dosage

Prior to LISRAYA treatment initiation, consider performing the following:

Active and latent tuberculosis (TB) infection evaluation: If positive, treat for TB prior to LISRAYA treatment .

Viral hepatitis screening in accordance with clinical guidelines: LISRAYA is not recommended in patients with active hepatitis B or hepatitis C .

A complete blood count: Avoid LISRAYA in patients with an absolute lymphocyte count less than 500 cells/mm3, absolute neutrophil count less than 1,000 cells/mm3, or hemoglobin level less than 8 g/dL .

Baseline hepatic and renal function tests: LISRAYA is not recommended in patients with severe hepatic or severe renal impairment .

Pregnancy Status: Verify the pregnancy status of females of reproductive potential prior to treatment with LISRAYA .

Update immunizations according to current immunization guidelines .

The recommended dosage of LISRAYA is 30 mg once daily, administered orally with or without food .

Infections

If a patient develops a serious infection, including serious opportunistic infection, interrupt LISRAYA treatment until the infection resolves or is adequately treated. .

Laboratory Abnormalities

Interruption of LISRAYA treatment may be needed for management of laboratory abnormalities as described in Table 1

.

Laboratory Measure | Action

Absolute Neutrophil Count (ANC) | Interrupt LISRAYA treatment if ANC is less than 1,000 cells/mm3; treatment may be restarted once ANC returns above this value

Absolute Lymphocyte Count (ALC) | Interrupt LISRAYA treatment if ALC is less than 500 cells/mm3; treatment may be restarted once ALC returns above this value

Hemoglobin (Hb) | Interrupt LISRAYA treatment if Hb is less than 8 g/dL; treatment may be restarted once Hb returns above this value

Hepatic transaminases (ALT/AST) | Interrupt LISRAYA treatment if drug-induced liver injury is suspected, until this diagnosis is excluded.

How to take Brepocitinib — instructions & advice from the label

Advise patients and caregivers to read the FDA-approved patient labeling (Medication Guide).

Serious Infections

Inform patients that they may be more likely to develop infections when taking LISRAYA. Instruct patients to contact their healthcare provider immediately during treatment if they develop any signs or symptoms of an infection .

Advise patients that the risk of herpes zoster infection is increased in patients taking LISRAYA and some cases can be serious .

Malignancies

Inform patients that LISRAYA may increase their risk of certain cancers and that periodic skin examinations should be performed while using LISRAYA. Instruct patients to inform their healthcare provider if they have ever had any type of cancer .

Advise patients to limit exposure to ultraviolet light (natural or artificial) by wearing protective clothing and using a broad-spectrum sunscreen.

Major Adverse Cardiovascular Events

Inform patients that LISRAYA may increase their risk of major adverse cardiovascular events (MACE) including myocardial infarction, stroke, and cardiovascular death. …

Warnings & precautions

Do not take this medicine if: LISRAYA is contraindicated in patients with a history of hypersensitivity reactions to brepocitinib or any of the excipients in LISRAYA .

LISRAYA increases the risk of infections, including serious bacterial, fungal, viral, and opportunistic infections that may lead to hospitalization or death. The most common serious infections reported with LISRAYA were pneumonia and sepsis . Other reported infections with use of JAK inhibitors, including LISRAYA, were tuberculosis, which may present with pulmonary or extrapulmonary disease, invasive fungal infections which may present with disseminated rather than localized disease, bacterial infections, viral infections (including herpes zoster), and other infections due to opportunistic pathogens.

Avoid use of LISRAYA in patients with an active, serious infection, including localized infections. Consider the risks and benefits of treatment prior to initiating LISRAYA in patients:

with chronic or recurrent infection

who have been exposed to TB

with a history of a serious or an opportunistic infection

who have resided or traveled in areas of endemic TB or endemic mycoses; or

with underlying conditions that may predispose them to infection.

Closely monitor patients for signs and symptoms of infection during and after treatment with LISRAYA. If a patient develops a serious infection, including a serious opportunistic infection, interrupt LISRAYA treatment until the infection resolves or is adequately treated. In patients who develop a new infection during treatment with LISRAYA, promptly complete diagnostic testing, initiate appropriate antimicrobial therapy, and monitor the patients closely. LISRAYA may be resumed once the infection resolves or is adequately treated.

Tuberculosis

Evaluate and test patients for latent and active TB infection prior to and during administration of LISRAYA. …

Brepocitinib side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Serious Infections

Mortality

Malignancy and Lymphoproliferative Disorders

Major Adverse Cardiovascular Events (MACE)

Thrombosis

Hypersensitivity Reactions

Gastrointestinal Perforations

Hypoglycemia in Patients with Diabetes

Laboratory Abnormalities

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of LISRAYA in adult patients with dermatomyositis was evaluated in a 52-week Phase 3, double-blind, placebo-controlled trial (Trial DM) . In this trial, 241 adult patients were randomized to receive LISRAYA 30 mg once daily (81 patients), brepocitinib 15 mg once daily (unapproved dosage) (81 patients), or placebo (79 patients) once daily for 52 weeks.

Table 2 summarizes the adverse reactions that occurred in ≥ 5% of LISRAYA-treated patients and ≥ 2% greater than placebo-treated patients in the 52-week placebo-controlled period. A total of 81 adult patients with dermatomyositis were exposed to LISRAYA during this period. …

Drug interactions

Smoking

Smoking causes induction of CYP1A1 and CYP1A2 levels. The exposure of brepocitinib in current smokers is lower than in non-current smokers, and therefore, the effectiveness of LISRAYA may be reduced in smokers .

Substrates of P-gp and BCRP

Brepocitinib is a P-gp and BCRP inhibitor. Concomitant use of LISRAYA with an orally administered P-gp or BCRP substrate may increase the systemic exposure of the P-gp or BCRP substrate .

Substrates of OCT2 or MATEs Transporters

Brepocitinib inhibits renal uptake transporters, OCT2 and MATEs (MATE1, MATE2-K) . Concomitant use of LISRAYA with drugs that are substrates of OCT2 and MATEs transporters may increase plasma concentrations of the substrates. Closely monitor patients when LISRAYA is concomitantly used with drugs that are substrates of OCT2 or MATEs transporters for which minimal concentration changes in substrate plasma concentration may lead to serious adverse reactions.

About this medicine

LISRAYA is formulated with the tosylate salt of brepocitinib, a TYK2/JAK1 inhibitor.

Brepocitinib tosylate is a white to off-white crystalline solid, slightly soluble in water and alcohol, with the following chemical name: [(1S)-2,2-difluorocyclopropyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone 4-methylbenzenesulfonate.

Brepocitinib tosylate has a molecular weight of 561.61 daltons (or 389.41 daltons as the free base) and a molecular formula of C25H29F2N7O4S. The chemical structure of brepocitinib tosylate is:

LISRAYA (brepocitinib) tablets are supplied for oral administration as 30 mg pink, capsule-shaped tablets. Each tablet of LISRAYA contains 30 mg of brepocitinib (equivalent to 43.27 mg brepocitinib tosylate) and the inactive ingredients hydroxypropyl methylcellulose, iron oxide red, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, titanium dioxide, and triacetin.

How it works: Brepocitinib is a Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5023a17b-e96a-67d4-e063-6394a90a14a7. Read the full official label on DailyMed.